Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
PAVmed Inc. (PAVM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/28/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/06/2023 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data |
| 04/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 03/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex... |
| 01/18/2023 |
8-K
| Quarterly results |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K
| Quarterly results |
| 09/09/2022 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ... |
| 08/16/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/26/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"PAVmed Inc. Senior Secured Convertible Note Issuance Date: April 4, 2022 Original Principal Amount: U.S. $27,500,000 FOR VALUE RECEIVED, PAVmed Inc., a Delaware corporation , hereby promises to pay to the order of [●] or its registered assigns the amount set forth above as the Original Principal Amount when due, whether upon the Maturity Date, on any Installment Date with respect to the Installment Amount due on such Installment Date , or upon acceleration, redemption or otherwise and to pay interest on the Outstanding Principal Value of this Note at the applicable Interest Rate from the date set forth above as the Issuance Date until the same becomes due and payable, whether upon the Maturity Date, on any Installment Date with respect to the Installment Amount due on such Installmen...",
"GRAUBARD MILLER The Chrysler Building , 11 th Floor 10174 March 31, 2022 PAVmed Inc. One Grand Central Place Suite 4600 10165",
"SECURITIES PURCHASE AGREEMENT , dated as of March 31, 2022, is by and among PAVmed Inc., a Delaware corporation with offices located at One Grand Central Place, Suite 4600, 10165 , and each of the investors listed on the Schedule of Buyers attached hereto .",
"W I T N E S S E T H : WHEREAS, the Company and each party listed as a “Buyer” on the Schedule of Buyers attached to the Securities Purchase Agreement are parties to the Securities Purchase Agreement, pursuant to which the Company shall be required to sell, and the Buyers shall purchase or have the right to purchase senior secured convertible notes of the Company issued pursuant thereto ; WHEREAS, it is a condition precedent to the Buyers’ obligation to purchase the Notes issued pursuant to each of the Securities Purchase Agreement that the Grantors shall have executed and delivered to the Collateral Agent this Agreement providing for the grant to the Collateral Agent, for the ratable benefit of itself and the Noteholders, of a valid, enforceable, and perfected security interest in certain ...",
"VOTING AGREEMENT VOTING AGREEMENT, dated as of April 4, 2022 , by and between PAVmed Inc., a Delaware corporation with offices located at One Grand Central Place, Suite 4600, 10165 and [________] . WHEREAS, the Company and certain investors have entered into a Securities Purchase Agreement, dated as of March 31, 2022 , pursuant to which, among other things, the Company has agreed to issue and sell to the Investors and the Investors have, severally but not jointly, agreed to purchase certain senior secured convertible notes of the Company , which will be convertible into shares of the Company’ s common stock, $0.001 par value per share , in accordance with the terms of the Notes; WHEREAS, as of the date hereof, the Stockholder owns [________] shares of Common Stock , which represent approxi...",
"Press release" |
|
| 04/01/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/29/2022 |
8-K
| Quarterly results |
| 03/08/2022 |
8-K
| Quarterly results |
| 03/03/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 02/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/25/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/18/2021 |
8-K
| Completion of Acquisition or Disposition of Assets Interactive Data |
| 10/07/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/12/2021 |
8-K
| Quarterly results |
| 08/10/2021 |
8-K
| Quarterly results |
| 08/03/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors NEW YORK, August 03, 2021 — PAVmed Inc. , a highly differentiated, multi-product, commercial-stage medical technology company, today announced that prominent global industry executive Aster Angagaw has joined the Board of Directors of its majority owned subsidiary Lucid Diagnostics Inc. . Ms. Angagaw will serve on the Company’ s Audit and Nominating Committees. “I am delighted to welcome Aster Angagaw to Lucid’ s Board of Directors,” said Lishan Aklog M.D., PAVmed’ s Chairman and Chief Executive Officer and Lucid’ s Executive Chairman. “She brings decades of business experience as a chief executive, global transformation leader, and public company director, with deep longstanding roots in ..." |
|
| 07/28/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/23/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 06/15/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/14/2021 |
8-K
| Quarterly results |
|
|
|